ACT for Rheumatoid Arthritis: Achieving Better Disease Control Beyond DMARDs | ALIV

Rheumatoid arthritis management has been transformed by disease-modifying antirheumatic drugs (DMARDs) — particularly biological agents (anti-TNF, anti-IL-6, anti-CD20, JAK inhibitors) — which have made remission an achievable target for many patients. Yet a meaningful proportion of RA patients on stable DMARD therapy continue to experience residual disease activity: some joint inflammation that is not fully controlled, persistent fatigue, and ongoing erosive progression despite adequate medical management. ACT's immunomodulatory layer is most clinically relevant for this specific patient group — those with stable but not fully controlled RA on existing therapy.

The Immune-Modulatory Rationale in Detail

The chronic synovial inflammation of RA involves a complex immune cell network: activated T-helper cells (Th1 and Th17) producing IL-17 and IFN-γ; activated B-cells producing rheumatoid factor and anti-CCP antibodies; macrophages producing TNF-α and IL-1β in the synovium; and a relative deficiency of Treg cells (regulatory T-cells) that would normally suppress this autoimmune activation. DMARD therapy targets specific nodes in this network (anti-TNF blocks TNF-α; anti-IL-6 blocks IL-6R; rituximab depletes B-cells). ACT's MSC-derived paracrine signals provide a broader immunoregulatory effect: IL-10 and TGF-β promote Treg expansion; IDO (indoleamine 2,3-dioxygenase) suppresses Th1 and Th17 activation; and PGE2 modulates macrophage polarisation toward the anti-inflammatory M2 phenotype.

This broader immunoregulatory mechanism is why ACT can provide meaningful additional benefit even in patients who have partially responded to biological therapy — it addresses aspects of the immune dysregulation that single-target biologics do not. The addition of ACT is not competitive with the existing DMARD — it is complementary, working through non-overlapping mechanisms. See the broader ACT RA context: ACT for rheumatoid arthritis — introduction.

Patient Selection Nuance

The RA patients most likely to benefit from ACT: DAS28 (disease activity score) of 2.6–4.4 (moderate disease activity) despite stable DMARD therapy; significant DMARD-resistant fatigue; coexisting fibromyalgia component (30% of RA patients have fibromyalgia — ACT addresses both through different mechanisms, unlike DMARDs which only address the RA component); and patients who have reached or are nearing the limit of available DMARD options and seek additional immunomodulatory support before or alongside biologic escalation. Patients with very active RA (DAS28 above 5.1) need DMARD optimisation first — ACT as an adjunct to inadequate treatment is not the appropriate sequence.

Does ACT produce measurable DAS28 improvement?

In ALIV's RA patients receiving ACT, DAS28 improvement at three months is the primary objective assessment point. Meaningful response is defined as a DAS28 reduction of 0.6 or more (the EULAR minimal clinically important difference). CRP and ESR reduction alongside DAS28 improvement confirms the biological response rather than symptomatic improvement alone. Response rates in appropriately selected RA patients are not as high as in OA patients — the more complex immune biology of RA produces more variable ACT responses — but meaningful benefit in appropriately selected patients is clinically observed.